How is the Graft Versus Host Disease (GVHD) Treatment Market Poised for Growth: Trends and Opportunities Through 2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the graft versus host disease (gvhd) treatment market?
The market size for treatment of graft versus host disease (GVHD) has seen substantial growth in recent years. The forecasted growth projects an increase from $2.85 billion in 2024 to $3.07 billion in 2025, showing a compound annual growth rate (CAGR) of 7.7%. Several factors contribute to this historical period of growth, including a higher frequency of allogeneic transplantations, a surge in acute GVHD cases, a boost in hematopoietic stem cell treatment rates, increased need for bone marrow transplants, a global rise in GVHD prevalence, growth in chronic GVHD cases, technological advancements, and an overall increase in patient population.
What will be the graft versus host disease (gvhd) treatment market size in the future?
The market size for the treatment of graft versus host disease (GVHD) is predicted to observe substantial expansion in the upcoming years, anticipated to reach $4.1 billion by the year 2029, with a compound annual growth rate (CAGR) of 7.5%. The forecast period’s growth can be associated with several factors including an increase in the figure of allogeneic transplantations, a rise in the occurrence of acute GVHD, a growing rate of hematopoietic stem cell treatments, a heightened demand for bone marrow transplants, a rising incidence of GVHD on a global scale, an escalation in chronic GVHD cases, and technological advancements. Key trends forecasted in this era incorporate partnerships, investments, product authorizations, and customizations.
Get your graft versus host disease (gvhd) treatment market report here!
What main drivers are fueling expansion in the graft versus host disease (gvhd) treatment market?
The growth of the graft versus host disease (GVHD) treatment market is anticipated to be spurred by the increasing instances of hematological disorders. These blood disorders cover a variety of conditions that impact blood and its components, such as red blood cells, white blood cells, platelets, and plasma. Factors contributing to these disorders include unhealthy lifestyle choices, genetic predisposition, and exposure to certain pollutants like radiation and chemicals. The GVHD treatment approaches developed to address GVHD can have wider implications for patients suffering from hematological disorders, offering new pathways for immune modulation and enhanced disease control. For instance, the Leukemia & Lymphoma Society, a US healthcare organization, projected that leukemia, lymphoma, and myeloma are likely to result in approximately 57,380 deaths in the US in 2023. This translates to roughly 157 people per day, or over six individuals per hour passing away from blood cancer. Hence, these escalating hematological disorders are fuelling the growth of the graft versus host disease (GVHD) treatment market.
What key areas define the segmentation of the global graft versus host disease (gvhd) treatment market?
The graft versus host disease (GVHD) treatment market covered in this report is segmented –
1) By Product Type: Corticosteroids, Monoclonal Antibodies, Immunosuppressants, Others
2) By Disease Type: Acute GvHD, Prophylaxis GvHD, Chronic GvHD
3) By End User: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone, Hydrocortisone, Betamethasone, Budesonide
2) By Monoclonal Antibodies: Anti-Inf Monoclonal Antibodies ( Infliximab, Adalimumab), Anti-il-2ra Monoclonal Antibodies ( Basiliximab), Anti-cd52 Monoclonal Antibodies (Alemtuzumab), Anti-il-6 Monoclonal Antibodies (Tocilizumab), Anti-Cd20 Monoclonal Antibodies (Rituximab)
3) By Immunosuppressants: Calcineurin Inhibitors (Cyclosporine, Tacrolimus), Methotrexate, Mycophenolate Mofetil, Azathioprine, Sirolimus (Rapamycin), Cyclophosphamide
4) By Others: Mesenchymal Stem Cells (Mscs), Jak Inhibitors ( Ruxolitinib), Extracorporeal Photopheresis (Ecp), Thalidomide, Antithymocyte Globulin (Atg), Colony-Stimulating Factors (Filgrastim)
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15579&type=smp
Who are the dominant players expanding their reach in the graft versus host disease (gvhd) treatment market?
Major companies operating in the graft versus host disease (GVHD) treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol Myers Squibb, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly And Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Biogen Inc., Astellas Pharma Inc., Jazz Pharmaceuticals plc, Allergan plc, Incyte Corporation, Mallinckrodt Pharmaceuticals, Genzyme Corporation, Kiadis Pharma, Neovii Pharmaceuticals AG, ElsaLys Biotech SA, Mesoblast Ltd., Soligenix
How are evolving market trends shaping graft versus host disease (gvhd) treatment Strategies?
Significant players in the graft versus host disease (GVHD) treatment market are focusing on the innovation and approval process of superior drugs to acquire a competitive advantage in the sector. The approval of products is crucial as they ensure the safety, effectiveness, and quality of healthcare products before being introduced to patients. For example, in March 2023, a healthcare firm from the US, Incyte corporation, managed to get their ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, approved by the Food and Drug Administration, another US-based healthcare entity. These tablets were designed for daily use to treat specific types of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15579
Which regions are emerging as leaders in the graft versus host disease (gvhd) treatment market?
North America was the largest region in the graft versus host disease (GVHD) treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the graft versus host disease (GVHD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Rare Diseases Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report
Vascular Grafts Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/vascular-grafts-global-market-report
Bone Grafts and Substitutes Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/bone-grafts-and-substitutes-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
